Integrin αL/ITGAL/CD11a Antibody (27): sc-135951

Integrin αL Antibody (27) is a mouse monoclonal IgG1 antibody that detects Integrin αL in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Integrin αL, also called CD11a, is a crucial component of the immune system, primarily expressed on leukocytes, where anti-Integrin αL antibody (27) plays a vital role in mediating cell adhesion and migration. Integrin αL is essential for the immune response, facilitating interaction between leukocytes and the endothelium during inflammation, allowing immune cells to exit the bloodstream and reach sites of infection or injury. The structure of Integrin αL, which consists of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail, enables conformational changes necessary for activation and function. These structural features allow Integrin αL to bind to ligands, such as intercellular adhesion molecules (ICAMs), effectively promoting cell-cell interactions critical for immune surveillance and response. Integrin αL monoclonal antibody (27) serves as an invaluable tool for researchers studying immune cell behavior, signaling pathways, and mechanisms underlying various inflammatory diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Integrin αL/ITGAL/CD11a Antibody (27) References:

1. Neutrophil inhibitory factor abrogates neutrophil adhesion by blockade of CD11a and CD11b beta(2) integrins.  |  Lo, SK., et al. 1999. Mol Pharmacol. 56: 926-32. PMID: 10531396
2. Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter.  |  Puig-Kröger, A., et al. 2000. J Biol Chem. 275: 28507-12. PMID: 10882733
3. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis.  |  Brouwer, RE., et al. 2001. Br J Haematol. 115: 298-308. PMID: 11703324
4. Epitope mapping of monoclonal antibody to integrin alphaL beta2 hybrid domain suggests different requirements of affinity states for intercellular adhesion molecules (ICAM)-1 and ICAM-3 binding.  |  Tang, RH., et al. 2005. J Biol Chem. 280: 29208-16. PMID: 15958383
5. Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes.  |  Timonen, T., et al. 1990. Int J Cancer. 46: 1035-40. PMID: 1979068
6. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.  |  Jilek, S., et al. 2014. Mult Scler. 20: 837-42. PMID: 24258149
7. Innate cell response in severe SARS-CoV-2 infection in children: Expression analysis of CD64, CD18 and CD11a.  |  García-Salido, A., et al. 2022. Med Intensiva (Engl Ed). 46: 50-53. PMID: 34991873
8. Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks.  |  Kim, JS., et al. 1995. J Neurol Sci. 128: 45-50. PMID: 7722533
9. Characterization of the CD11a (alpha L, LFA-1 alpha) integrin gene promoter.  |  Nueda, A., et al. 1993. J Biol Chem. 268: 19305-11. PMID: 8103515
10. Role of polymorphonuclear neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine malaria.  |  Senaldi, G., et al. 1994. Infect Immun. 62: 1144-9. PMID: 8132319

The preferred Integrin αL/ITGAL/CD11a antibody is Integrin αL/ITGAL/CD11a Antibody (E-1): sc-374172.